SAN FRANCISCO, February 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2023.

•Grew fourth quarter 2023 patient registrations in excess of 22% compared to the fourth quarter 2022

•Revenue of $132.5 million, a 17.7% increase compared to fourth quarter 2022

•Gross margin of 66.0%, a 390 basis point decrease compared to fourth quarter 2022

•Net loss of $38.7 million, an $18.5 million increased loss compared to fourth quarter 2022

•Adjusted EBITDA of $2.4 million, a $1.3 million improvement compared to fourth quarter 2022

•Cash, cash equivalents and marketable securities of $133.8 million at December 31, 2023, a $24.7 million reduction from September 30, 2023

•Revenue of $492.7 million, a 19.9% increase compared to full year 2022

•Gross margin of 67.3%, a 120 basis point decrease compared to full year 2022

•Net loss of $123.4 million, a $7.3 million increased loss compared to full year 2022

•Adjusted EBITDA of ($4.9) million, reflecting a $6.4 million improvement compared to full year 2022

•Second highest quarter of Zio long-term continuous monitoring new account openings in the United States during the fourth quarter and record full year of new account onboarding during 2023

•Zio monitor transition progressing with 67% of long-term continuous monitoring registrations now being for our newest generation ambulatory cardiac monitor

•Upcoming data presentations at the American College of Cardiology's Annual Scientific Session & Expo in Atlanta, GA, from April 6-8, 2024

"This past year was truly transformational for iRhythm as we made significant strides to advance our mission in our core U.S. market while advancing multiple initiatives that set us up for future growth,” said Quentin Blackford, iRhythm’s President and CEO. “We realized 20% revenue growth for the full year, driven by record new account onboarding, balanced volume contributions from multiple channels, and the largest product launch in company history. We've made significant progress towards international expansion efforts with recent EU MDR CE mark approval, completed market evaluation in Switzerland, and ongoing review of our Japanese regulatory submission. Moreover, we are also realizing value from our increased focus on operational discipline, achieving more than 180-basis points of improvement in adjusted EBITDA margin for the full year 2023 compared to 2022 and setting us up for sustainable improvements on our path towards our long-range plan."

"In 2024, we expect to continue bringing our platform technology to as many patients who can benefit through continued commercial execution, product innovation, expansion into new markets, pilots in exciting new business models, and exploration into new adjacent market opportunities. As we continue to bring our Zio services to millions of patients globally and scale the business, we could not be more excited by our unique position in this fast-growing market and our ability to drive value for patients, physicians, health systems, and shareholders," concluded Mr. Blackford.

Revenue for the three months ended December 31, 2023, increased 17.7% to $132.5 million, from $112.6 million during the same period in 2022. The increase was primarily attributable to increases in the volume of Zio Services resulting from increased demand, partially offset by a slight decline in average selling price.

Gross profit for the fourth quarter of 2023 was $87.4 million, up from $78.7 million during the same period in 2022, while gross margins were 66.0% as compared to 69.9% during the same period in 2022. The decrease in gross margin was primarily due to increases in headcount-related costs associated with scaling our clinical operations organization as well as costs related to the commercial launch of Zio monitor.

Operating expenses for the fourth quarter of 2023 were $126.6 million, compared to $99.4 million for the same period in 2022 and $110.1 million in Q3 2023. Sequentially, the increased spend was driven by an impairment charge totaling $11.1 million, related to a reduction in the capitalized leased asset value of our San Francisco office from continued declining commercial real estate rental market conditions, as well as increases for legal, regulatory, and consulting fees.

Net loss for the fourth quarter of 2023 was $38.7 million, or a diluted loss of $1.26 per share, compared with net loss of $20.2 million, or a diluted loss of $0.67 per share, for the same period in 2022.

Revenue for the year ended December 31, 2023, increased 19.9% to $492.7 million, from $410.9 million in 2022. The increase in revenue was primarily due to increased volume of Zio services provided as a result of increased demand.

Gross profit for the year was $331.8 million, up from $281.6 million in 2022, while gross margin was 67.3%, a decline from 68.5% in 2022.

Operating expenses for the year were $457.0 million, an increase of 15.6% compared to 2022. The increase was mainly due to an increase in headcount-related costs to support the advancement of our product development and growth in our business.

Net loss for 2023 was $123.4 million, or a diluted loss of $4.04 per share, compared with net loss of $116.2 million, or a diluted loss of $3.88 per share in 2022.

Cash, cash equivalents and short-term investments were $133.8 million as of December 31, 2023.

iRhythm projects revenue for the full year 2024 to grow to approximately $575 million to $585 million. Gross margin for the full year 2024 is expected to range from 68% to 69% and adjusted EBITDA margin for the full year 2024 is expected to range from approximately 3% to 4% of revenues.

iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event, which will be available on the investors section of the Company’s website at investors.irhythmtech.com.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2024 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, impairment and restructuring charges, and business transformation costs.

We exclude the following items from non-GAAP financial measures for adjusted net loss, adjusted net loss per share and adjusted operating expenses:

•impairment and restructuring charges, and

•business transformation costs to scale the organization.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-K expected to be filed on or about February 22, 2024. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Stephanie Zhadkevich

(919) 452-5430

investors@irhythmtech.com

Saige Smith

(262) 289-7065

irhythm@highwirepr.com

			(Unaudited) Three Months Ended December 31,												Year Ended December 31,
			2023						2022						2023						2022
Revenue, net			$	132,511					$	112,617					$	492,681					$	410,921
Cost of revenue			45,085						33,910						160,875						129,289
Gross profit			87,426						78,707						331,806						281,632
Operating expenses:
Research and development			15,416						12,675						60,244						46,610
Selling, general and administrative			100,114						86,730						385,645						322,198
Impairment and restructuring charges			11,078						—						11,078						26,608
Total operating expenses			126,608						99,405						456,967						395,416
Loss from operations			(39,182)						(20,698)						(125,161)						(113,784)
Interest expense			(941)						(1,013)						(3,650)						(4,138)
Interest and other income, net			1,679						1,586						6,155						2,036
Loss before income taxes			(38,444)						(20,125)						(122,656)						(115,886)
Income tax provision			255						73						750						269
Net loss			$	(38,699)					$	(20,198)					$	(123,406)					$	(116,155)
Net loss per common share, basic and diluted			$	(1.26)					$	(0.67)					$	(4.04)					$	(3.88)
Weighted-average shares, basic and diluted			30,702						30,151						30,528						29,916